Indian Pharmaceutical Market- The Blue eyed Industrycipmma.com/wp-content/uploads/2018/07/aiocd_presentation.pdfAn overview of Indian & Tamil Nadu Pharmaceutical Market Presented to:

Indian Pharmaceutical Market- The Blue eyed Industry An overview of Indian & Tamil Nadu Pharmaceutical Market

Presented to: CIPMMA

Hari Natarajan, Sujata G 10th June 2012

A

B

C

E

D

F

A

D

MARKET

Indian Pharma Market Dynamics

South Zone Split

A C

A

C

IPM & Tamil Nadu Market Compared

Way Forward

Parameters Emerging trends, Market Dynamics, Competition Mapping, New Introductions , Opportunities

Objective: Indian Pharmaceutical Market & Tamil Nadu Market Overview

C E

Factors for Success

Opportunity Market in Tamil Nadu

A

B

C

E

D

F

A

D

MARKET


South Zone Split

A C

A

C


Way Forward



C E

Factors for Success


(Val in Crs) Dataset : PharmaTrac Apr MAT 2012

16%

14%

13%

With a CAGR of 14.7%.. IPM grows despite all odds…..


Oct- Dec (Q3-11) – GR has dipped considerably over last year

Q1-12 shows highest growth of 19% & has added value of the same period last year

Market adds on value QOQ………………..

11,57712,502

14,345 14,12113,216

14,307

16,277 16,53715,740

5,706

0

2,000

4,000

6,000

8,000

10,000

12,000

14,000

16,000

18,000

Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 (Apr)

GR 13.2 10.8 17.2 14.5 14.2 14.4 13.5 17.1 19.1


63,747 Cr IPM growing @ 16% - Top Corporates

Top 10 corporates contribute 42% of IPM

7 corporates in top 10 out growing the IPM

•Abbott+Abbott HC+Solvay •Alkem+Indchemie+Cachet •Pfizer+Wyeth •Zydus+Biochem

GR 17.1 13.7 16.5 23.7 14.3 13.5 16.5 18.0 22.9 16.6

3741

3335

2956 29352781 2774

2166 2120 2015 1914

0

500

1000

1500

2000

2500

3000

3500

4000

ABBOTT* CIPLA GSK SUN ZYDUS* RANBAXY ALKEM* MANKIND PFIZER* LUPIN


63,747 Cr IPM growing @ 16% - Top Companies

Top 10 companies contribute 38% of IPM

6 companies in top 10 out growing the IPM

GR 13.7 16.5 23.7 13.5 15.7 14.5 18.0 18.6 16.6 38.6

3,335

2,956 2,9352,774

2,5442,459

2,1201,935 1,914

1,530

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

CIPLA GSK SUN RANBAXY ABBOTT HC

ZYDUS MANKIND ALKEM LUPIN MACLEODS


Maximum Bonus given by Mankind followed by Cipla

Mankind clearly shows 2 rank loss after excluding the bonus component

Macleods have entered the top 10 category, but ranks 12th in actual sales

SV- Sales Val

AV- Actual Val

BV- Bonus Val

Bonus split bares it all………

SV AV COMPANY SV AV BV Bonus % to SV

0 0 IPM 63747 61358 2390 3.7%

1 1 CIPLA 3335 3006 329 9.9%

2 2 GSK 2956 2899 57 1.9%

3 3 SUN 2935 2897 38 1.3%

4 4 RANBAXY 2774 2688 85 3.1%

5 5 ABBOTT HC 2544 2479 65 2.6%

6 6 ZYDUS CADILA 2459 2309 151 6.1%

7 9 MANKIND 2120 1715 405 19.1%

8 8 ALKEM 1935 1821 114 5.9%

9 7 LUPIN 1914 1871 43 2.2%

10 12 MACLEODS 1530 1438 93 6.1%

RANK Apr-12


Mankind bonus percentage is highest and is no 1 bonus offering company

Cipla though 2nd in Bonus, has not lost its rank

SV- Sales Val

AV- Actual Val

BV- Bonus Val

Mankind leaders of bonus……..loses rank on actual value

SV AV BV COMPANY SV AV BV Bonus % to SV

0 0 0 IPM 63747 61358 2390 3.7%

7 9 1 MANKIND 2120 1715 405 19.1%

1 1 2 CIPLA 3335 3006 329 9.9%

6 6 3 ZYDUS CADILA 2459 2309 151 6.1%

12 13 4 ARISTO 1484 1356 129 8.7%

8 8 5 ALKEM 1935 1821 114 5.9%

10 12 6 MACLEODS 1530 1438 93 6.1%

4 4 7 RANBAXY 2774 2688 85 3.1%

5 5 8 ABBOTT HC 2544 2479 65 2.6%

2 2 9 GSK 2956 2899 57 1.9%

17 18 10 MICRO LABS 1218 1170 49 4.0%

RANK Apr-12


Top 10 drive IPM….next 40 on fast lane…..

37.99%

26.94%

16.47%

11.57%

7.03%

IPM MS Apr 11

Top 10

11 to 25

26- 50

51-100

100+

38.44%

27.16%

16.63%

11.73%

6.04%

IPM MS Apr 12

Apr-11 Apr-12

IPM 14.4% 16.4%

Top 10 14.9% 17.8%

11 to 25 19.6% 17.3%

26- 50 15.0% 17.5%

51-100 10.1% 18.0%

100+ 1.0% 0.1%

MAT VAL GR


IPM showing more growth with Chronic products

Cipla, Ranbaxy, Abbott HC, Mankind, Alkem, Lupin, Macleods – Chronic driving growth rate

Macleods growing at highest pace in the acute category amongst top 10

Acute leads…….chronic drives….

20.7% 17.4% 16.2% 23.6% 15.1% 20.3% 14.3% 27.8% 54.8% 18.6% 42.6%

16.7% 11.8% 16.5% 23.7% 13.1% 13.9% 14.6% 16.7% 17.0% 15.4% 37.9%GR

75%

63%

96%

45%

83%

71%76%

87%95%

62%

83%

25%

37%

4%

55%

17%

29%24%

13%5%

38%

17%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

IPM CIPLA GSK SUN RANBAXY ABBOTT HC ZYDUS CADILA

MANKIND ALKEM LUPIN MACLEODS

ACUTE CHRONIC


Volume is major driving force and all top growing companies are driven by volume growth

Good NI (EM) growth seen for Ranbaxy, Macleods and Mankind

Good NI (NM) growth seen for Macleods, Sun and Ranbaxy

Fig ( ) indicate Val Growth

Brand building leading to growth……….

8.5 8.9

14.9 14.3

4.0

9.86.0

10.7 10.213.1

20.73.6 3.4

0.93.4

0.7

2.8

3.6

1.0 2.4

-1.6

5.4

3.51.0

0.7

3.2

6.5

2.4

3.4

5.5 5.2 4.0

9.5

0.8

0.4

0.1

2.8

2.3

0.71.5

0.8 0.9 1.1

3.0

-6

-3

0

3

6

9

12

15

18

21

24

27

30

33

36

39

42

Vol GR Price GR GR from EM GR from NM


Double digit growth across most

therapies

9 therapies outgrowing market

growth

Anti Neoplastics followed by Anti

Diabetic show high growth

Among Top 10 therapies, Anti

Diabetic followed by Cardiac are driving

growth

Diabetes the silent killer ……moves up ranks

SUPERGROUP MAT VAL Salience GR Incre VAL

IPM 63747 100.00% 16.4 8977

ANTI-INFECTIVES 11545 18.11% 11.8 1215

CARDIAC 7566 11.87% 21.0 1311

GASTRO INTESTINAL 7243 11.36% 13.6 867

VITAMINS / MINERALS / NUTRIENTS 5681 8.91% 20.3 958

RESPIRATORY 4989 7.83% 14.5 630

PAIN / ANALGESICS 4800 7.53% 14.4 603

GYNAECOLOGICAL 4204 6.59% 15.1 552

ANTI DIABETIC 4177 6.55% 29.2 944

NEURO / CNS 3839 6.02% 15.2 507

DERMA 3346 5.25% 18.2 515

OPHTHAL / OTOLOGICALS 1068 1.68% 12.6 119

HORMONES 1053 1.65% 18.0 161

OTHERS 858 1.35% 19.4 139

VACCINES 822 1.29% 10.6 79

BLOOD RELATED 763 1.20% 20.0 127

ANTI-NEOPLASTICS 586 0.92% 22.3 107

ANTI MALARIALS 580 0.91% 10.3 54

SEX STIMULANTS / REJUVENATORS 339 0.53% 19.0 54

STOMATOLOGICALS 290 0.45% 12.6 32


Volume growth drives the market growth followed by New Products

Business thrives on volumes….NIs act as cushion

8.5 7.611.7

7.54.8 7.0 5.8 6.8

21.6

8.0 6.8

3.6

-0.4

6.4

2.6 8.2 3.63.5

4.8

3.9

3.8 6.1

3.5

3.6

1.8

2.9

7.1

2.9 3.92.8

3.3

2.53.3

0.8

1.0

1.1

0.7

0.2

0.9 1.10.7

0.5

1.01.9

-5.0

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

Vol GR Price GR GR from EM GR from NM

Fig ( ) indicate Val Growth


Therapy – Anti Infective

Anti infective is the largest contributing therapy to the IPM

Macleods shows maximum growth 36% and gained 2 ranks followed by GSK at 20%

Highest increment by Macleods (Amikamac-20 Crs, Sensiclav-17 Crs, Maczone- 12 Crs) followed by

Alkem (Clavam-38 Crs, Taxim O–15 Crs)

Companies who have added on ranks are MSD (+4), Akumentis (+55)

Apr-12 G/L COMPANY VAL MAT MAT VAL MS MS(G/L) MAT VAL GR INCRE VAL

0 0 ANTI-INFECTIVES 11545 100.00% 0.00% 11.8 1215

1 0 ALKEM 963 8.34% 0.30% 15.9 132

2 1 GSK 907 7.86% 0.53% 19.9 150

3 -1 RANBAXY 834 7.22% -0.55% 3.8 31

4 0 CIPLA 802 6.95% -0.28% 7.4 55

5 2 MACLEODS 704 6.10% 1.08% 35.9 186

6 -1 ARISTO 704 6.10% -0.42% 4.5 31

7 -1 MANKIND 616 5.33% -0.19% 8.0 45

8 1 ABBOTT HEALTHCARE 552 4.78% 0.00% 11.8 58

9 -1 LUPIN 548 4.75% -0.18% 7.8 40

10 0 FDC 384 3.33% -0.28% 3.0 11

Rank Apr-12


Therapy – Cardiac

Cardiac therapy is outgrowing the IPM

Sun growing has highest Growth 26% with increment of 118 Crs (Aztor -16 Cr)

Ranbaxy gained 3 rank with Growth of 24%

Unichem loses its market share due to poor Growth of 3%

Companies that have gained ranks are Gland Pharma (+14), Glenmark (+3), Micro & Astra (+1)


0 0 CARDIAC 7566 100.00% 0.00% 21.0 1311

1 0 SUN 580 7.66% 0.28% 25.6 118

2 1 ZYDUS CADILA 463 6.12% 0.05% 22.0 83

3 -1 LUPIN 456 6.03% -0.12% 18.6 72

4 0 CIPLA 402 5.31% -0.28% 14.8 52

5 0 ABBOTT HEALTHCARE 391 5.17% -0.09% 18.8 62

6 1 SANOFI-AVENTIS 336 4.44% 0.01% 21.2 59

7 3 RANBAXY 333 4.40% 0.12% 24.4 65

8 1 TORRENT 323 4.27% -0.08% 18.6 51

9 -1 INTAS 317 4.19% -0.21% 15.1 42

10 -4 UNICHEM 313 4.14% -0.72% 3.1 9

Rank Apr-12


Therapy – Gastro Intestinal

5 out of top 10 outgrowing the market

Sun shows highest growth of 30% and increment of 95 Crs (Pantocid-17 Crs, Pantocid L- 14 Crs)

followed by Alkem with 29% growth and 71 Crs increment(Pan-33 Crs, Pan D-21 Crs)

Solvay also shows high Growth of 18%

Companies that have gained ranks are Pfizer & Medley (+3), Alembic (+4), Akumentis (+36)


0 0 GASTRO INTESTINAL 7243 100.00% 0.00% 13.6 867

1 0 ZYDUS CADILA 449 6.20% -0.06% 12.6 50

2 0 SUN 418 5.78% 0.71% 29.5 95

3 2 ALKEM 319 4.40% 0.52% 28.7 71

4 -1 DR. REDDYS 316 4.37% -0.15% 9.8 28

5 -1 ARISTO 297 4.10% 0.14% 17.5 44

6 1 CIPLA 263 3.63% 0.05% 15.1 35

7 -1 MANKIND 254 3.51% -0.14% 9.2 21

8 0 CADILA 225 3.11% -0.13% 8.9 18

9 0 ABBOTT HEALTHCARE 222 3.06% -0.06% 11.4 23

10 2 SOLVAY 197 2.73% 0.10% 17.9 30

Rank Apr-12


South Leading, But East shows maximum Growth…

Rank Company MAT Value MS

Apr-12 Apr-11 Apr-12 Apr-12 Apr-11 Apr-12

0 NORTH ZONE 14,713 17,349 100.00% 10.9% 17.9%

1 CIPLA 1,038 1,154 6.65% 15.7% 11.1%

2 GSK 722 889 5.12% 11.4% 23.1%

3 RANBAXY 640 774 4.46% -2.4% 21.0%

4 MANKIND 653 763 4.40% 32.8% 16.9%

5 ZYDUS CADILA 633 724 4.17% 13.0% 14.3%

6 ABBOTT HC 574 648 3.73% -0.1% 12.9%

7 PFIZER 390 564 3.25% 25.0% 44.6%

8 LUPIN 490 549 3.16% 22.1% 11.9%

9 MACLEODS 379 539 3.11% 23.5% 42.1%

10 SUN 436 512 2.95% 23.7% 17.4%

ValueMAT MAT Val GRRank Company MAT Value MS


0 SOUTH ZONE 15,668 18,404 100.00% 14.7% 17.5%

1 SUN 942 1,222 6.64% 23.5% 29.8%

2 GSK 838 952 5.17% 16.2% 13.6%

3 RANBAXY 800 941 5.11% 14.2% 17.6%

4 CIPLA 771 928 5.04% 9.2% 20.4%

5 ABBOTT HC 572 684 3.71% 8.6% 19.5%

6 ZYDUS CADILA 589 672 3.65% 14.0% 14.2%

7 MICRO LABS 462 506 2.75% 4.2% 9.5%

8 LUPIN 376 484 2.63% 24.7% 28.5%

9 MANKIND 377 459 2.49% 28.0% 21.5%

10 DR. REDDYS 408 443 2.41% 9.8% 8.5%

ValueMAT MAT Val GR


South Leading, But East shows maximum Growth…

Rank Company MAT Value MS


0 EAST ZONE 10,622 12,738 100.00% 14.7% 19.9%

1 ALKEM 514 642 5.04% 21.8% 25.0%

2 SUN 495 612 4.80% 17.8% 23.6%

3 RANBAXY 541 580 4.56% 9.8% 7.2%

4 ABBOTT HC 459 572 4.49% 8.8% 24.6%

5 GSK 470 550 4.32% 10.5% 17.0%

6 ZYDUS CADILA 356 463 3.64% 15.6% 30.2%

7 CIPLA 384 459 3.60% 6.5% 19.4%

8 LUPIN 331 414 3.25% 23.8% 24.9%

9 ARISTO 355 391 3.07% 12.0% 10.3%

10 MANKIND 284 344 2.70% 34.2% 21.1%

ValueMAT MAT Val GRRank Company MAT Value MS


0 WEST ZONE 13,767 15,256 100.00% 17.9% 10.8%

1 CIPLA 739 795 5.21% 28.5% 7.5%

2 ABBOTT HC 594 641 4.20% 13.0% 7.8%

3 ZYDUS CADILA 570 601 3.94% 30.2% 5.4%

4 SUN 501 589 3.86% 23.8% 17.6%

5 GSK 507 565 3.70% 15.8% 11.5%

6 MANKIND 482 555 3.63% 26.5% 15.0%

7 RANBAXY 463 478 3.14% -0.3% 3.2%

8 LUPIN 444 468 3.07% 30.7% 5.4%

9 INTAS 350 438 2.87% 22.1% 25.2%

10 ALKEM 377 424 2.78% 19.8% 12.4%

ValueMAT MAT Val GR


Augmentin rules supreme…………Januvia makes it count…

BRAND SUBGROUP COMPANY SV MAT 12 AV MAT 12 GR% Incre

Apr-12 G/L IPM 63747.2 61357.5 16.4 8976.9

1 0 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID | J1C4 GSK 301.3 272.8 28.2 66.3

2 0 COREX CHLORPHENIRAMINE + CODEINE | R5E1 PFIZER 254.7 249.5 28.0 55.7

3 0 HUMAN MIXTARD

INTERMEDIATE-ACTING, ISPOPHANE

(NPH) | A10C4 NOVO NORDISK 227.8 227.0 16.0 31.4

4 2 REVITAL GINSENG COMBINATIONS | A11X24 RANBAXY 210.3 206.1 24.2 40.9

5 -1 MONOCEF CEFTRIAXONE | J1D17 ARISTO 200.7 157.8 8.0 15.0

6 -1 VOVERAN DICLOFENAC | M1A12 NOVARTIS 199.6 186.7 7.9 14.6

7 3 VOLINI DICLOFENAC | M2A2 RANBAXY 172.7 161.0 24.4 33.8

8 3 DEXORANGE IRON FERROUS COMBINATION | B3A2 FRANCO 167.2 158.5 21.6 29.7

9 0 BETADINE POVIDONE IODINE | D8A2 WIN-MEDICARE 166.6 166.3 19.1 26.7

10 4

PHENSEDYL

COUGH LINCTUS CHLORPHENIRAMINE + CODEINE | R5E1 ABBOTT HC 165.3 164.4 13.5 31.2

11 1 CALPOL PARACETAMOL | N2B1 GSK 163.5 157.0 19.1 26.3

12 -4 TAXIM O CEFIXIME | J1D26 ALKEM 161.4 161.3 10.0 14.6

13 -6 TAXIM CEFOTAXIME | J1D13 ALKEM 157.4 145.3 6.3 9.3

14 24 JANUVIA SITAGLIPTIN | A10B66 MSD 156.5 156.5 78.4 68.8

15 -2 ASTHALIN SALBUTAMOL | R3A11 CIPLA LTD. 154.6 152.1 12.9 17.7

16 6 CLAVAM AMOXYCILLIN + CLAVULANIC ACID | J1C4 ALKEM 152.5 133.5 31.9 36.9

17 1 MANFORCE SILDENAFIL | G4E1 MANKIND 145.8 37.3 22.4 26.7

18 -2 ACILOC RANITIDINE | A2B4 CADILA 143.2 143.0 9.1 12.0

19 1 LIV 52 HEPATIC PROTECTORS INCLUDING AYURVEDIC | A5D3HIMALAYA 140.4 140.1 20.9 24.3

20 3 BECOSULES B COMPLEX | A11E8 PFIZER 138.7 137.4 20.3 23.4

Rank


Telma H, Mixtard 30 HM Pen fill have entered the top 20 league in Chronic Brands Cardace, Huminsulin ,Aten & Losar H– are slipping -big losses in rank

Human Mixtard rules supreme……

RANK G/L BRAND SUBGROUP COMPANY MAT VAL APR 12 ACTUAL MAT VAL APR 12 MAT VAL GR APR 12 INCRE VAL

CHRONIC 15730 15668 20.7 2702

1 0 HUMAN MIXTARD INTERMEDIATE-ACTING, ISPOPHANE (NPH) | A10C4 NOVO NORDISK 228 227 16.0 31

2 6 JANUVIA SITAGLIPTIN | A10B66 MSD 156 156 78.4 69

3 -1 ASTHALIN SALBUTAMOL | R3A11 CIPLA 155 152 12.9 18

4 7 JANUMET SITAGLIPTIN + METFORMIN | A10B68 MSD 133 133 63.0 52

5 -2 SEROFLO SALMETEROL + FLUTICASONE | R3A18 CIPLA 122 122 11.2 12

6 4 GLYCOMET GP GLIMEPIRIDE + METFORMIN | A10B11 USV 116 116 39.3 33

7 0 FORACORT FORMOTERAL + BUDESONIDE | R3A6 CIPLA 113 113 26.0 23

8 -4 CARDACE RAMIPRIL | C9A13 SANOFI-AVENTIS 110 109 17.5 16

9 0 STORVAS ATORVASTATIN | C10A1 RANBAXY 101 101 16.9 15

10 -4 HUMINSULIN INTERMEDIATE-ACTING, ISPOPHANE (NPH) | A10C4 ELI LILLY 95 95 4.6 4

11 -6 ATEN ATENOLOL | C7A5 ZYDUS CADILA 94 93 3.5 3

12 0 AEROCORT LEVOSALBUTAMOL + BECLOMETHASONE | R3A33 CIPLA 91 91 11.9 10

13 0 EPTOIN PHENYTOIN | N3A12 ABBOTT INDIA 89 89 15.1 12

14 6 TELMA TELMISARTAN | C9D4 GLENMARK 87 86 55.3 31

15 0 ATORVA ATORVASTATIN | C10A1 ZYDUS CADILA 84 84 25.5 17

16 9 TELMA H TELMISARTAN + HYDROCLORTHIAZIDE | C9I8 GLENMARK 80 80 52.3 28

17 12 MIXTARD 30 HM PENFILL INTERMEDIATE-ACTING, ISPOPHANE (NPH) | A10C4 NOVO NORDISK 80 80 59.1 30

18 1 AMARYL GLIMEPIRIDE | A10B4 SANOFI-AVENTIS 76 76 27.2 16

19 -2 BUDECORT BUDESONIDE | R3A3 CIPLA 76 69 19.9 13

20 -6 LOSAR H LOSARTAN + HYDROCLORTHIAZIDE | C9I7 UNICHEM 72 72 -1.6 -1


Corex dares Augmentin…… 46 Crs the difference…..

Apr-12 G/L BRAND SUBGROUP COMPANY MAT SAL VAL MAT ACT VAL MAT VAL GR Incre VAL

0 0 ACUTE TOTAL 48018 45690 15.0 6274.6

1 0 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID | J1C4 GSK 301 273 28.2 66.3

2 0 COREX CHLORPHENIRAMINE + CODEINE | R5E1 PFIZER 255 250 28.0 55.7

3 2 REVITAL GINSENG COMBINATIONS | A11X24 RANBAXY 210 206 24.2 40.9

4 -1 MONOCEF CEFTRIAXONE | J1D17 ARISTO 201 158 8.0 15.0

5 -1 VOVERAN DICLOFENAC | M1A12 NOVARTIS 200 187 7.9 14.6

6 3 VOLINI DICLOFENAC | M2A2 RANBAXY 173 161 24.4 33.8

7 3 DEXORANGE IRON FERROUS COMBINATION | B3A2 FRANCO INDIAN 167 159 21.6 29.7

8 0 BETADINE POVIDONE IODINE | D8A2 WIN-MEDICARE 167 166 19.1 26.7

9 5

PHENSEDYL

COUGH LINCTUS CHLORPHENIRAMINE + CODEINE | R5E1 ABBOTT HC 165 164 13.5 31.2

10 1 CALPOL PARACETAMOL | N2B1 GSK 164 157 19.1 26.3

11 -4 TAXIM O CEFIXIME | J1D26 ALKEM 161 161 10.0 14.6

12 -6 TAXIM CEFOTAXIME | J1D13 ALKEM 157 145 6.3 9.3

13 7 CLAVAM AMOXYCILLIN + CLAVULANIC ACID | J1C4 ALKEM 153 134 31.9 36.9

14 2 MANFORCE SILDENAFIL | G4E1 MANKIND 146 37 22.4 26.7

15 -2 ACILOC RANITIDINE | A2B4 CADILA 143 143 9.1 12.0

16 2 LIV 52

HEPATIC PROTECTORS INCLUDING

AYURVEDIC | A5D3 HIMALAYA 140 140 20.9 24.3

17 4 BECOSULES B COMPLEX | A11E8 PFIZER 139 137 20.3 23.4

18 -6 ZIFI CEFIXIME | J1D26 FDC 135 134 2.4 3.2

19 0 ZINETAC RANITIDINE | A2B4 GSK 135 134 16.3 18.8

20 5 CEFTUM CEFUROXIME | J1D12 GSK 134 131 28.0 29.3

RANK Apr-12


20 Brands with Highest Incremental of IPM exc bonus


New Launches gallery – Combinations are the buzz…..

SUB GRP LD Apr-11 Apr-12

NI(Last 24 months) 76.0 540.2

CEFIXIME + AZITHROMYCIN | J1D68 Sep-10 4.8 43.5

SILVER NITRATE | D8A11 Jul-11 0.0 39.2

CEFPODOXIME + OFLOXACIN | J1D70 Oct-10 5.3 33.6

FLUPIRTINE | M1A142 Aug-10 6.1 24.0

TELMISARTAN + METOPROLOL | C7G4 May-10 4.3 23.1

LEVOSULPIRIDE + PANTOPRAZOLE | A3F50 Dec-10 2.6 17.8

TAPENTADOL | N2A13 May-11 0.0 16.6

AMLODIPINE + OLMESARTAN + HYDROCLORTHIAZIDE | C8B15 Aug-10 2.2 16.6

MONTELUKAST + FEXOFENADINE | R6A36 Nov-10 2.3 16.0

INTERFERON ALPHA | J5A2 Oct-11 0.0 15.0

DAPOXETINE | G4X8 Nov-10 2.0 12.0

LEVOCLOPERASTINE | R5G18 Dec-10 1.6 11.4

LIRAGLUTIDE | A10B61 Jun-10 1.4 11.0

LEVOSULPIRIDE + ESOMEPRAZOLE | A3F49 Dec-10 2.0 10.7

CINITAPRIDE + PANTOPRAZOLE | A3F44 May-10 5.1 10.7

TELMISARTAN + AMLODIPINE + HYDROCLORTHIAZIDE | C9E21 Dec-10 0.2 10.2

OLMESARTAN + METOPROLOL | C7G3 May-10 2.0 7.8

SILODOSIN | G4C16 Aug-11 0.0 7.0

GABAPENTIN + NORTRIPTYLINE | N3A27 Apr-11 0.0 6.7

LACOSAMIDE | N3A25 Jul-10 1.6 6.6

LAFUTIDINE + DOMPERIDONE | A3F43 Oct-10 1.0 6.4

MAT Val


Top Brands in New Molecules

Rank BRAND COMPANY LD MAT Value Apr 11 MAT Value Apr 12 MAT VAL MS Apr 12

0 CEFIXIME + AZITHROMYCIN | J1D68 4.8 43.5 100.00%

1 ZIMNIC AZ ABBOTT HC Sep-10 4.8 19.5 44.82%

2 ZITHROX PLUS MACLEODS Apr-11 0.0 8.0 18.36%

3 ZIFI AZ FDC Jun-11 0.0 6.7 15.33%

4 AZIFINE C GLENMARK Aug-11 0.0 2.0 4.54%

5 HIFEN AZ HETERO Nov-11 0.0 1.5 3.40%

0 SILVER NITRATE | D8A11 0.0 39.2 100.00%

1 SILVEREX IONIC RANBAXY Jul-11 0.0 39.2 100.00%

0 CEFPODOXIME + OFLOXACIN | J1D70 5.3 33.6 100.00%

1 GUDCEF PLUS MANKIND Oct-10 0.8 7.9 23.52%

2 MACPOD O MACLEODS Nov-10 2.0 6.7 19.89%

3 ZEDOCEF O MACLEODS Nov-10 1.8 5.9 17.55%

4 CEPODEM O RANBAXY Apr-11 0.1 3.8 11.31%

5 POLYPOD O MACLEODS Feb-11 0.3 2.5 7.36%

0 FLUPIRTINE | M1A142 6.1 24.0 100.00%

1 KATADOL LUPIN Oct-10 2.5 7.3 30.58%

2 SNEPDOL SUN INDUSTRIES Aug-10 1.8 4.7 19.48%

3 RETENSE SUN INDUSTRIES Apr-11 0.1 4.2 17.68%

4 LUPIRTIN LUPIN Aug-10 1.7 3.4 14.02%

5 PRUF INTAS Jun-11 0.0 1.6 6.68%

0 TELMISARTAN + METOPROLOL | C7G4 4.3 23.1 100.00%

1 METOSARTAN SUN INDUSTRIES Nov-10 1.5 10.1 43.90%

2 TELSAR BETA UNICHEM May-10 1.9 4.4 19.08%

3 TELMAXX GLENMARK Aug-10 0.8 2.8 12.27%

4 TELLZY MT ALEMBIC Apr-11 0.0 1.5 6.40%

5 TETAN BETA ALEMBIC Apr-11 0.0 1.2 5.37%




0 TAPENTADOL | N2A13 0.0 16.6 100.00%

1 TYDOL RANBAXY May-11 0.0 3.4 20.39%

2 VORTH TP GLENMARK May-11 0.0 3.2 19.07%

3 TRANSDOL LUPIN Jun-11 0.0 2.3 14.04%

4 TAPENTA ZUVENTUS Jun-11 0.0 1.5 8.99%

5 ZYNTAP ZYDUS CADILA Jul-11 0.0 1.0 6.00%

0 AMLODIPINE + OLMESARTAN + HYDROCLORTHIAZIDE | C8B152.2 16.6 100.00%

1 TRIOLMEZEST SUN INDUSTRIES Dec-10 0.9 6.7 40.44%

2 OLMAT AM H MICRO LABS Aug-10 0.7 3.3 20.12%

3 OLSAVAS 3 ORCHID CHEMICALS & Jan-11 0.2 2.3 14.04%

4 TRI OLMESAR MACLEODS Feb-11 0.1 2.3 13.87%

5 OLMIN AH ERIS LIFE SCIENCES Oct-10 0.2 0.7 4.28%

0 MONTELUKAST + FEXOFENADINE | R6A36 2.3 16.0 100.00%

1 MONTAIR FX CIPLA Dec-10 0.9 6.3 39.62%

2 MONTEMAC FX MACLEODS Nov-10 1.2 5.6 34.90%

3 HISTAFREE M MANKIND Mar-11 0.0 1.6 10.14%

4 LUKOTAS FX INTAS Nov-10 0.1 0.8 4.71%

5 MONTI FX ABBOTT HC Jan-12 0.0 0.6 3.76%

0 INTERFERON ALPHA | J5A2 0.0 15.0 100.00%

1 PEGIHEP ZYDUS CADILA Oct-11 0.0 15.0 100.00%

0 DAPOXETINE | G4X8 2.0 12.0 100.00%

1 SUSTINEX EMCURE Nov-10 1.1 2.8 23.52%

2 KUTUB HETERO May-11 0.0 2.1 17.71%

3 STAY TAL ZYDUS CADILA Apr-11 0.1 1.1 9.32%

4 DA SUTRA HETERO May-11 0.0 1.1 9.30%

5 DURAJECT AKUMENTIS Mar-11 0.1 1.1 9.15%




0 LEVOCLOPERASTINE | R5G18 1.6 11.4 100.00%

1 LUPITUSS LUPIN Jan-11 1.0 4.8 42.32%

2 ZEROTUSS ARISTO Dec-10 0.5 4.3 38.07%

3 SOVENTUS DC ZUVENTUS May-11 0.0 1.4 12.38%

4 TUSSMARK MANKIND Aug-11 0.0 0.6 5.38%

5 TUSCURE AKUMENTIS Aug-11 0.0 0.2 1.86%

0 LIRAGLUTIDE | A10B61 1.4 11.0 100.00%

1 VICTOZA NOVO NORDISK INDIA Jun-10 1.4 11.0 100.00%

0 LEVOSULPIRIDE + ESOMEPRAZOLE | A3F49 2.0 10.7 100.00%

1 SOMPRAZ L SUN INDUSTRIES Dec-10 2.0 10.7 100.00%

0 CINITAPRIDE + PANTOPRAZOLE | A3F44 5.1 10.7 100.00%

1 CINTODAC ZYDUS CADILA May-10 5.1 10.7 100.00%

0 TELMISARTAN + AMLODIPINE + HYDROCLORTHIAZIDE | C9E21 0.2 10.2 100.00%

1 TAZLOC TRIO USV Apr-11 0.0 3.0 29.74%

2 TAH INTAS Jan-11 0.1 2.0 19.88%

3 TELMA AMH GLENMARK May-11 0.0 1.9 18.44%

4 TELMED AH MEDLEY Dec-10 0.1 0.8 8.25%

5 TELVAS 3D ARISTO Oct-11 0.0 0.5 5.32%


6618 brands launched….. & still counting

BRAND SUBGROUP COMPANY LD MAT Value MAT Act Val

NI (last 24 months) 3144.3 3076.8

SILVEREX IONIC SILVER NITRATE | D8A11 RANBAXY Jul-11 39.2 37.4

REMYLIN D METHYLCOBALAMIN COMBINATIONS | A11F3 ERIS Dec-10 27.6 27.5

SENSICLAV AMOXYCILLIN + CLAVULANIC ACID | J1C4 MACLEODS Jun-10 22.1 20.4

NUROKIND LC METHYLCOBALAMIN COMBINATIONS | A11F3 MANKIND Oct-10 20.4 20.4

ZIMNIC AZ CEFIXIME + AZITHROMYCIN | J1D68 ABBOTT HC Sep-10 19.5 18.3

PREVENAR 13 PNEUMONIA | J7A7 WYETH Oct-10 18.1 18.1

NEW TRIGLUCORED FORTE GLIBENCLAMIDE + METFORMIN + PIOGLITAZONE | A10B52 SUN Oct-10 17.8 17.8

NUFIL FILGRASTIM | L3A2 RANBAXY Aug-11 17.7 17.7

MIXTARD 30 PLAIN HUMAN INSULINS | A10C10 NOVO NORDISK Jul-10 17.5 17.5

PANTOCID L LEVOSULPIRIDE + PANTOPRAZOLE | A3F50 SUN Dec-10 17.0 17.0

ALL 9 METHYLCOBALAMIN COMBINATIONS | A11F3 AKUMENTIS Nov-10 16.8 16.3

RABONIK PLUS LEVOSULPIRIDE + RABEPRAZOLE | A3F47 ERIS Jul-10 16.4 16.3

NEWBONA PLUS CALCIUM CARBONATE + CALCITRIOL | A12A20 AKUMENTIS Nov-10 16.0 15.9

PEGIHEP INTERFERON ALPHA | J5A2 ZYDUS CADILA Oct-11 15.0 15.0

CASPORAN CASPOFUNGIN | J2A20 RANBAXY Sep-11 13.2 13.2

TOZABACT PIPERACILLIN + TAZOBACTAM | J1H8 RANBAXY May-11 12.6 12.6

ZIFEXIM CEFIXIME + OFLOXACIN | J1D45 RANBAXY Jun-10 11.9 10.2

HEPTRAL S-ADENOSYL METHIONINE | V6D4 ABBOTT Sep-10 11.7 11.7

ISTAVEL SITAGLIPTIN | A10B66 SUN Jun-11 11.7 11.7

GEMCAL DS SG OTHER CALCIUM + CALCITRIOL | A12A24 ALKEM Sep-10 11.4 11.4

Industry Summary

IPM growing at 16%

Q1- Jan- Mar 2012 has shown highest growth.

Top 10 companies contributing 38% to IPM, of which 6 companies are outgrowing IPM

Point to note is also that many companies who were lower down the order have started growing up

on a fast pace

Volume of existing products driving growth for IPM

Anti Neoplastics and Anti Diabetics are the highest growing categories

Anti infectives show highest value, although all categories growing at a consistent rate, making entry level

decisions difficult

Value wise South zone leads, however in growth East predominates

A

B

C

E

D

F

A

D

MARKET


South Zone Split

A C

A

C


Way Forward



C E

Factors for Success



AP leads…. Tamil Nadu keeps up the pace


South Zone & Tamil Nadu market adds on Value….


South Regions on an increasing spree………

A

B

C

E

D

F

A

D

MARKET


South Zone Split

A C

A

C


Way Forward



C E

Factors for Success



Indian Pharma Market Tamil Nadu Market

Market Shows an Increasing Trend with Robust Growths…

IPM has grown by 16% with an increment Of 8977 Crs Cipla is the No 1 Company with 3335 Crs Augmentin (301 Crs) rules followed by Corex (255 Crs) & Human Mixtard (228 Crs)

TN has grown by 17% with an increment Of 767 Crs Sun is the No 1 Company with 451 Crs Human Mixtard (28 Crs) rules followed by Volini , Revital & Gelusil MPS(25 Crs) & Augmentin (24 Crs)


Gelusil MPS & Phexin gets high contribution from TN……


COMPANY ALL INDIA TAMIL NADU % CONT of TN to AI

MARKET 63747 5297 8.31%

SUN PHARMA 2935 451 15.36%

GLAXOSMITHKLINE 2956 307 10.38%

RANBAXY 2774 283 10.20%

CIPLA LTD. 3335 253 7.59%

ABBOTT HEALTHCARE 2544 190 7.47%

WOCKHARDT 1241 178 14.36%

LUPIN 1914 178 9.28%

ZYDUS CADILA 2459 158 6.43%

MICRO LABS 1218 148 12.16%

PFIZER 1497 148 9.85%

Sun, Wockhardt, Micro gets high contribution from TN……


Cardiac No 1…. Anti-Diabetic moves up in TN


OADs rule Tamil Nadu……Insulins also grow……

Top 10 groups contribute to 32% of the market

Anti-histamine market also a 100 Cr market in Tamil Nadu


VAL APR 11 VAL APR 12 MS 2011 MS 2012 VAL GR INCRE VAL

TAMILNADU MARKET 4530 5297 - - 16.9 767

Above 25 Crs 0 28 0.00% 0.53% - 28

11 to 25 Crs 476 653 10.51% 12.33% 37.2 177

6 to 10 Crs 481 642 10.62% 12.12% 33.5 161

1 to 5 Crs 2507 2837 55.34% 53.56% 13.2 330

<1 Crs 1066 1137 23.53% 21.46% 6.7 71

Brands in the range of 1-5 Crs dominate

Brands in the bracket of 6-25 Crs adds up to 44% of incremental value Human Mixtard moves from No 6 position to No 1 in 2012 24% of brands are below 1 Cr in the market


Chronic does well in TN….grows at 20%

Amongst Acute Care Volini, Revital & Gelusil share honours in Tami Nadu

Amongst Chronic, Human Mixtard leads followed by Asthalin & Huminsulin

A

B

C

E

D

F

A

D

MARKET


South Zone Split

A C

A

C


Way Forward



C E

Factors for Success



Anti-infectives rule IPM…. Cardiac in partnership in TN


Amoxy –Clav biggest earners in IPM…. Infant Formulas in TN

Tamil Nadu Market Summary

IPM growing at 16%, Tamil Nadu grows at 17%

Top 10 companies contributing 38% to IPM, whereas in TN its 43%

Point to note is also that many companies who were lower down the order have started growing up

on a fast pace

Volume of existing products driving growth for IPM & TN

Value wise South Zone leads.

Andhra Pradesh & Tamil Nadu close in race

Electronic Data Exchange Electronic data Exchange also know as EDE offers for the first time ever get Electronic Data of Secondary Sales. Used for variety of purpose including moving field to secondary targets, replenishment based supplies to stockists, streamlining production planning & CFA stock allocation as well as reviews and early information throughout the sales, marketing & distribution. It satisfies the Basic Need of the Pharma Industry that ‘s unmet for decades. EDE would also provide accurate data on expiry dates of brands with month & batch numbers which would eliminate returns thereby ensuring more profitable business & bottom lines

PharmaTrac The preferred Sales Data Audit of many. Having multiple advantages like early information, additional parameters like stock levels & bonus details, excellence in client servicing, accurate pricing & immediate new product reporting – more than 3 dozen clients have shifted to Pharma Trac in 2 years.

Drug Info A unique Mobile drug database with over170,000 packs and 70000 brands from over 6000 companies. Useful for Doctors & Retailers alike who can get the latest prices updated monthly and the most comprehensive drug database that updates new products on weekly basis. For top 100 companies – guaranteed 100% products, including latest launches, are updated. Drug Info is available through SMS, GPRS & Internet – its instant and affordable access to quality information including the various packs of a brand and MRP.

Our Offerings to the Industry

Documents

Indian Pharmaceutical Market- The Blue eyed Industrycipmma.com/wp-content/uploads/2018/07/aiocd_presentation.pdfAn overview of Indian & Tamil Nadu Pharmaceutical Market Presented to: